Development of HB-EGF-CTF related therapy and biomarker for gastrointestinal cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 24590923
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Nagoya City University
• Principal Investigator: Shimura Takaya 名古屋市立大学, 医学(系)研究科(研究院), 講師 (90405192)
• Co-Investigator(Kenkyū-buntansha): EBI Masahide 愛知医科大学, 医学部, 講師 (40611629) ; YOSHIDA Michihiro 名古屋市立大学, 医学研究科, 研究員 (20636328)
• Co-Investigator(Renkei-kenkyūsha): HIGASHIYAMA Shigeki 愛媛大学, 大学院医学系研究科, 教授 (60202272)
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: HB-EGF / 胃癌 / 大腸癌 / EGFR

Outline of Final Research Achievements

HB-EGF expression, not intracellular localization of HB-EGF-CTF, in the tumor was one of the predictive factor for anti-EGFR therapy against KRAS wild type metastatic ｃolorectal cancer, as well as other EGFR ligands including amphiregulin, TGF-a, epiregulin (Yoshida M, Shimura T, et al. J Cancer Res Clin Oncol.2013: 367-78).
Urinary level and tumor expression of ADAM12, which regulates HB-EGF-CTF nuclear translocation, is a useful biomarker for early diagnosis of gastric cancer(Yoshida M, Shimura T, et al. J Cancer Res Clin Oncol.2013: 367-78).

Free Research Field

消化器内科